Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hemoglobinuria, Paroxysmal 4Carcinoma, Hepatocellular 3Squamous Cell Carcinoma of Head and Neck 2Neuroblastoma 2Neoplasms 2Melanoma 2Liver Diseases 2Leukemia 2Hodgkin Disease 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liver Neoplasms 1Histiocytosis 1Hemoglobinuria 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × Antibodies × Clear all
NCT05259397 2023-03-08

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Pfizer

Phase 1 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡